Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts

Medical Oncology

Volumn 32, Issue 5, 2015, Pages 1-9

  Hernandez, James R ^a   Kim, John J ^a,d,e   Verdone, James E ^a   Liu, Xin ^a   Torga, Gonzalo ^a   Pienta, Kenneth J ^a,b,c   Mooney, Steven M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Johns Hopkins University   (United States)

^d University of California   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD44; E cadherin (CDH1); Epithelial to mesenchymal transition (EMT); OVOL1 2; RBM35A ESRP1 epithelial splicing regulatory protein 1; ZEB1

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD44V ANTIGEN; CD44V6 ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19; EPITHELIAL SPLICING REGULATORY PROTEIN 1; MEMBRANE PROTEIN; PROTEIN GRHL2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSCRIPTION FACTORS OVOL1; TRANSCRIPTION FACTORS OVOL2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; EPITHELIAL CANCER CELL LINE; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; MESENCHYME CELL; PLASTICITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; WESTERN BLOTTING; EPITHELIUM CELL; GENETICS; HUMAN; MALE; MESENCHYMAL STROMA CELL; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANTIGENS, CD44; CELL LINE, TUMOR; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MEMBRANE PROTEINS; MESENCHYMAL STROMAL CELLS; PROSTATIC NEOPLASMS;

EID: 84927137590     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0593-z     Document Type: Article

References (33)

1. Yang KR, Mooney SM, Zarif JC, Coffey DS, Taichman RS, Pienta KJ. Niche inheritance: a cooperative pathway to enhance cancer cell fitness though ecosystem engineering. J Cell Biochem. 2014;115(9):1478–85. doi:10.1002/jcb.24813.
2. Mooney SM. Chemotherapy increases aggressiveness of prostate cancer via epithelial mesenchymal transition. Cell Biol Res Ther. 2013;. doi:10.4172/2324-9293.1000105.
3. Roca H, Hernandez J, Weidner S, McEachin RC, Fuller D, Sud S, et al. Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS One. 2013;8(10):e76773. doi:10.1371/journal.pone.0076773.
4. Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal. 2014;26(10):2234–9. doi:10.1016/j.cellsig.2014.07.011.
5. Marzese DM, Liu M, Huynh JL, Hirose H, Donovan NC, Huynh KT, et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res. 2015;28(1):82–93. doi:10.1111/pcmr.12307.
6. Lau WM, Teng E, Chong HS, Lopez KA, Tay AY, Salto-Tellez M, et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014;74(9):2630–41. doi:10.1158/0008-5472.CAN-13-2309.
7. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringner M, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer. 2011;11:418. doi:10.1186/1471-2407-11-418.
8. Mooney SM, Parsana P, Hernandez JR, Liu X, Verdone JE, Torga G, et al. The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor. J Cell Biochem. 2015;116(1):115–23. doi:10.1002/jcb.24948.
9. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Investig. 2011;121(3):1064–74. doi:10.1172/JCI44540.
10. Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, et al. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem. 2013;114(6):1286–93. doi:10.1002/jcb.24464.
11. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S et al. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. Embo J. 2010;29(19):3286–300.
12. Zuo J, Guo Y, Peng X, Tang Y, Zhang X, He P, et al. Inhibitory action of pristimerin on hypoxiamediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells. Oncol Rep. 2015;. doi:10.3892/or.2015.3708.
13. Shiraishi T, Verdone JE, Huang J, Kahlert UD, Hernandez JR, Torga G et al. Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget. 2014;6(1):130–43.
14. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7. doi:10.1038/nature11003.
15. Mooney SM, Rajagopalan K, Williams BH, Zeng Y, Christudass CS, Li Y, et al. Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses. J Cell Biochem. 2011;112(4):1066–75. doi:10.1002/jcb.23020.
16. Mooney SM, Grande JP, Salisbury JL, Janknecht R. Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry. 2010;49(1):1–10. doi:10.1021/bi901263m.
17. Mooney SM, Goel A, D’Assoro AB, Salisbury JL, Janknecht R. Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. J Biol Chem. 2010;285(40):30443–52. doi:10.1074/jbc.M110.143792.
18. Zeng Y, Wodzenski D, Gao D, Shiraishi T, Terada N, Li Y, et al. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res. 2013;73(13):4123–33. doi:10.1158/0008-5472.CAN-12-1343.
19. Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, et al. Characterization and clinical relevance of ALDHbright populations in prostate cancer. Clin Cancer Res. 2013;19(19):5361–71. doi:10.1158/1078-0432.CCR-12-2857.
20. Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, et al. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. J Cell Biochem. 2014;115(9):1505–15. doi:10.1002/jcb.24805.
21. Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate. 2014;74(6):602–17. doi:10.1002/pros.22775.
22. Zhao S, He JL, Qiu ZX, Chen NY, Luo Z, Chen BJ, et al. Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis. Asian Pac J Cancer Prev APJCP. 2014;15(16):6761–6.
23. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–56. doi:10.1016/j.stem.2014.01.009.
24. Yu P, Zhou L, Ke W, Li K. Clinical significance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol. 2010;136(8):1283–92. doi:10.1007/s00432-010-0779-x.
25. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65(1):13–24.
26. Gupta A, Cao W, Sadashivaiah K, Chen W, Schneider A, Chellaiah MA. Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9. Sci World J. 2013;2013:493689. doi:10.1155/2013/493689.
27. Tei H, Miyake H, Harada K, Fujisawa M. Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy. Urol Oncol. 2014;32(5):694–700. doi:10.1016/j.urolonc.2013.12.002.
28. Aaltomaa S, Lipponen P, Ala-Opas M, Kosma VM. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol. 2001;39(2):138–44.
29. Noordzij MA, van Steenbrugge GJ, Verkaik NS, Schroder FH, van der Kwast TH. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res. 1997;3(5):805–15.
30. Rajagopalan K, Qiu R, Mooney SM, Rao S, Shiraishi T, Sacho E, et al. The Stress-response protein prostate-associated gene 4, interacts with c-Jun and potentiates its transactivation. Biochim Biophys Acta. 2014;1842(2):154–63. doi:10.1016/j.bbadis.2013.11.014.
31. Wang J, Xiao L, Luo CH, Zhou H, Zeng L, Zhong J, et al. CD44v6 promotes beta-catenin and TGF-beta expression, inducing aggression in ovarian cancer cells. Mol Med Rep. 2015;. doi:10.3892/mmr.2015.3145.
32. Lange T, Samatov TR, Tonevitsky AG, Schumacher U. Importance of altered glycoprotein-bound N- and O-glycans for epithelial-to-mesenchymal transition and adhesion of cancer cells. Carbohydr Res. 2014;389:39–45.
33. Reinke LM, Xu Y, Cheng C. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. J Biol Chem. 2012;287(43):36435–42.